Phase II
The company will continue to analyze data regarding the secondary endpoints.
The decision to carry on came after dosing for the Phase III GENERATION HD1 trial was halted following an overall risk/benefit assessment.
The problem Kinaset is trying to solve is that over time, patients receiving asthma therapies – typically inhaled corticosteroids plus bronchodilators – become steroid-refractory.
Unlike antibody-drug conjugates (ADCs) that focus on antigens, PDCs are able to target the tumor microenvironment that has universal features across solid tumors.
To alleviate the problem of antibiotic-resistant bacteria, or superbugs, several biotechnology companies are developing different strategies to target and kill these microorganisms.
Affini-T Therapeutics unveiled its mission to target oncogenic driver mutations to deliver transformative therapies intended to cure patients.
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look.
The company’s vision for the next few years includes annual revenue of $5 billion by 2025 and the approval of at least five novel products by the end of the decade.
Looking at long-term growth, Michael said that will be driven by numerous differentiated assets across each of Abbvie’s core areas.
BridgeBio Pharma had inked a non-exclusive clinical partnership with Amgen to study a combination of its BBP-398 with Amgen’s Lumakras in advanced solid tumors with the KRAS G12C mutation.
PRESS RELEASES